Rockley Photonics Announces Receipt of Notice from NYSE of Non-Compliance with Continued Listing Standards
16 December 2022 - 8:15AM
Business Wire
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global medical technology company focused on delivering leading
edge silicon photonics-based biosensing solutions by targeting a
portfolio of biomarkers, today announced that it received a notice
from the New York Stock Exchange (“NYSE”) on December 9, 2022,
indicating that the Company is not in compliance with NYSE’s
continued listing standards, which require an average market
capitalization of not less than $50 million over a 30 trading-day
period and stockholders’ equity of not less than $50 million. The
notice has no immediate impact on the listing of Rockley’s common
stock on the NYSE, subject to the Company’s compliance with the
NYSE’s other continued listing requirements, except that its ticker
symbol will continue to have an added designation of “.BC” to
indicate the status of its ordinary shares as below compliance with
the NYSE continued listing standards. The “.BC” indicator will be
removed when it regains compliance.
Rockley intends to respond to the NYSE within ten business days
of receipt of the notice of its intent to submit a business plan to
the NYSE within 45 days that shows how the Company plans to regain
compliance with this continued listing standard within 18 months
from the date of the notice. If Rockley is unable to regain
compliance, the NYSE may initiate procedures to suspend and delist
its common stock.
About Rockley Photonics
Formed in 2013, Rockley is a global medical technology company
focused on delivering leading edge silicon photonics-based
biosensing solutions that target a portfolio of biomarkers.
Rockley's ground-breaking end-to-end biosensing platform unlocks
unique spectra-based biomarkers enabling insights into personal
health and well-being. With next-generation biosensing platforms
specifically designed for mobile health monitoring, Rockley is
laying the foundation for a new generation of biomedical
applications across multiple industries.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “enhance”,
“estimate,” “eventual,” “expand, “expect,” “focus,” “forward,”
“future,” “goal,” “ground-breaking” “intend,” “may,” “might,”
“opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “revolutionize,” “seem,”
“should,” “trend,” “vision,” “will,” “would” or other terms that
predict or indicate future events, trends, or expectations, and
similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) our intent
to regain compliance with the NYSE’s continued listing
requirements; and (b) our belief that we are laying the foundation
for a new generation of applications across multiple industries,
and the extent to which we may expand our focus beyond biosensing
solutions.
Forward-looking statements are subject to several risks,
assumptions, and uncertainties (many of which are beyond Rockley’s
control) that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks, assumptions, and uncertainties include,
but are not limited to, the factors described under the heading
“Risk Factors” in our Annual Report on Form 10-K and in other
documents we file with the Securities and Exchange Commission. If
any of these risks or uncertainties materialize, or should any of
these assumptions prove incorrect, actual results may differ
materially from those discussed in or implied by these
forward-looking statements. There can be no assurance that future
developments affecting Rockley will be those that have been
anticipated. Given these risks and uncertainties, you should not
place undue reliance on these forward-looking statements. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221215005946/en/
Gwyn Lauber Rockley Photonics Telephone: +1 626-995-0001 Email:
investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Jan 2025 to Feb 2025
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Feb 2024 to Feb 2025